Status:
WITHDRAWN
Characterizing the Intestinal Hormonal Secretion in Non-obese, Obese and Non-obese Patients After Bariatric Surgery
Lead Sponsor:
Dr. Ofir Harnoy MD
Collaborating Sponsors:
Hadassah Medical Organization
Conditions:
Obesity
Eligibility:
All Genders
18-85 years
Brief Summary
The enteroendocrine system is composed from different cells along the different parts of the gastrointestinal tract, secreting diverse hormones and bariatric surgery alters intestinal hormone secretio...
Detailed Description
Obesity and Diabetes Mellitus (DM) impose a significant burden of morbidity on many individuals around the world. In recent years, the enteroendocrine cells system with its diverse hormones (Glucagon,...
Eligibility Criteria
Inclusion
- \>18 years
- BMI\>= 35 or BMI\<=25 or 6-12 months after RYGB surgery
Exclusion
- Known HIV infection
- Any NSAID'S usage in the last 3 months
- Known Celiac disease
- Concomitant disease with potential small bowel or colonic involvement (Tb, sarcoidosis, IBD, microscopic colitis etc')
- Pregnancy
- Participation in another clinical trial
- Any use of medications known to modulate glucagon levels such as GLP1 analogs, DPP4 inhibitors and/or SGLT2 inhibitors.
- Insulin-treated patients.
- Declined to sign an informed consent
Key Trial Info
Start Date :
December 1 2018
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
July 16 2020
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT03399097
Start Date
December 1 2018
End Date
July 16 2020
Last Update
July 20 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Sheba Medical Center
Tel Litwinsky, Israel, 52621